CYTALUX Dose Extension Study

Inclusion Criteria:

1. Male and female patients 18 years of age and older
2. Primary diagnosis, or a high clinical suspicion, of cancer in the lung warranting surgery based on CT/PET or other imaging obtained within 4 months of the screening visit, or have a primary diagnosis for ovarian cancer
3. Scheduled to undergo surgical thoracoscopy for wedge resection or anatomic lung resection, or ovarian cancer debulking/cytoreduction
4. Willingness of research participant or legal guardian/representative to give written informed consent

Exclusion Criteria:

1. History of anaphylactic reactions to products containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation.
2. History of allergy to any of the components of Cytalux™ (pafolacianine)
3. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol or follow-up schedule
4. Known sensitivity to fluorescent light
5. Impaired renal function defined as eGFR\< 50 mL/min/1.73m2
6. Impaired liver function defined as values \> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>2x ULN for total bilirubin excluding those patients with Gilbert's syndrome
7. Pregnant and/or lactating women
8. Administration of folate, folic acid, or folate-containing supplements 48 hours before administration of Cytalux™ (pafolacianine)